# OnCo record cares-310 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/cares-310/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "cares-310", "NCT03764293" ;
  schema:name "CARES-310"@en ;
  schema:description "A PD-1 antibody plus an oral anti-VEGF pill beat sorafenib on survival, one of the largest benefits seen in liver cancer."@en ;
  schema:url <https://onco.cc/trials/cares-310/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT03764293>, <https://www.cancernetwork.com/view/fda-issues-second-camrelizumab-rivoceranib-crl-in-hepatocellular-carcinoma> ;
  onco:status "positive" ;
  onco:phase "3" ;
  schema:startDate "2019-06-10" ;
  onco:related <https://onco.cc/collections/src-cancer-network/> ;
  onco:cancers <https://onco.cc/cancers/hcc/> ;
  onco:technologies <https://onco.cc/technologies/antiangiogenic/>, <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  onco:drugs <https://onco.cc/drugs/camrelizumab-rivoceranib/> ;
  onco:companies <https://onco.cc/companies/hengrui/> ;
  onco:people <https://onco.cc/people/qin-shukui/> .